Skip to main content
Top
Published in: Clinical Rheumatology 3/2015

Open Access 01-03-2015 | Original Article

The influence of Multiwave Locked System (MLS) laser therapy on clinical features, microcirculatory abnormalities and selected modulators of angiogenesis in patients with Raynaud’s phenomenon

Authors: Anna Kuryliszyn-Moskal, Jacek Kita, Agnieszka Dakowicz, Sylwia Chwieśko-Minarowska, Diana Moskal, Bożena Kosztyła-Hojna, Ewa Jabłońska, Piotr Adrian Klimiuk

Published in: Clinical Rheumatology | Issue 3/2015

Login to get access

Abstract

The aim of this study was to investigate the influence of the Multiwave Locked System (MLS) laser therapy on clinical features, microvascular changes in nailfold videocapillaroscopy (NVC) and circulating modulators releasing as a consequence of vascular endothelium injury such as vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) in patients with primary and secondary Raynaud’s phenomenon. Seventy-eight RP patients and 30 healthy volunteers were recruited into the study. All patients with RP received MLS laser irradiation for 3 weeks. Clinical, NVC and laboratory investigations were performed before and after the MLS laser therapy. The serum concentration of VEGF and Ang-2 were determined by an enzyme-linked immunosorbent assay (ELISA). After 3 weeks of MLS laser therapy, the clinical improvement manifested by decreasing of the number of RP attacks, mean duration of Raynaud’s attack and pain intensity in RP patients was observed. After MLS laser therapy in 65 % of patients with primary and in 35 % with secondary RP, an increase in the loop number and/or a reduction in avascular areas in NVC were observed. In comparison with a control group, higher serum concentration of VEGF and Ang-2 in RP patients was demonstrated. After MLS laser therapy, a reduction of Ang-2 in both groups of RP patients was found. Our results suggest that NVC may reflect microvascular changes associated with clinical improvement after MLS laser therapy in patients with primary and secondary RP. Ang-2 serum levels may be a useful marker of microvascular abnormalities in RP patients treated with MLS laser therapy.
Literature
3.
go back to reference Kurosaka D, Hirai K, Nishioka M, Miamoto Y, Yoshida K et al (2010) Clinical significance of serum levels of vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in patients with rheumatoid arthritis. J Rheumatol 37:1121–1128CrossRefPubMed Kurosaka D, Hirai K, Nishioka M, Miamoto Y, Yoshida K et al (2010) Clinical significance of serum levels of vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in patients with rheumatoid arthritis. J Rheumatol 37:1121–1128CrossRefPubMed
4.
go back to reference Westra J, deGroot L, Plaxton SL, Brouwer E, Posthumus MD et al (2011) Angiopoietin-2 is highly correlated with inflammation and disease activity in recent-onset rheumatoid arthritis and could be predictive for cardiovascular disease. Rheumatology 50:665–673CrossRefPubMed Westra J, deGroot L, Plaxton SL, Brouwer E, Posthumus MD et al (2011) Angiopoietin-2 is highly correlated with inflammation and disease activity in recent-onset rheumatoid arthritis and could be predictive for cardiovascular disease. Rheumatology 50:665–673CrossRefPubMed
5.
go back to reference Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242–248CrossRefPubMed Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242–248CrossRefPubMed
6.
go back to reference Reiss Y, Droste J, Heil M, Tribulova S, Schmidt MHH, Schaper W, Dumont DJ, Plate KH (2007) Angiopoietin-2 impairs revascularisation after limb ischaemia. Circ Res 101(1):88–96CrossRefPubMed Reiss Y, Droste J, Heil M, Tribulova S, Schmidt MHH, Schaper W, Dumont DJ, Plate KH (2007) Angiopoietin-2 impairs revascularisation after limb ischaemia. Circ Res 101(1):88–96CrossRefPubMed
7.
go back to reference Riccieri V, Stefanantoni K, Vasile M, Macri V, Sciarra I, Iannace N, Alessandri C, Valesini G (2011) Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis. Clin Exp Rheumatol 29(65):S46–S52PubMed Riccieri V, Stefanantoni K, Vasile M, Macri V, Sciarra I, Iannace N, Alessandri C, Valesini G (2011) Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis. Clin Exp Rheumatol 29(65):S46–S52PubMed
8.
go back to reference Cutolo M, Grassi W, Matucci Cernic M (2003) Raynaud’s phenomenon and the role of capillaroscopy. Arthritis Rheum 48:3023–3030CrossRefPubMed Cutolo M, Grassi W, Matucci Cernic M (2003) Raynaud’s phenomenon and the role of capillaroscopy. Arthritis Rheum 48:3023–3030CrossRefPubMed
9.
go back to reference Lambova SN, Müller-Ladner U (2009) The role of capillaroscopy in differentiation of primary and secondary Raynaud’s phenomenon in rheumatic diseases: a review of the literature and two case reports. Rheumatol Int 29:1263–1271CrossRefPubMed Lambova SN, Müller-Ladner U (2009) The role of capillaroscopy in differentiation of primary and secondary Raynaud’s phenomenon in rheumatic diseases: a review of the literature and two case reports. Rheumatol Int 29:1263–1271CrossRefPubMed
10.
go back to reference De Angelis R, Grassi W, Cutolo M (2009) A growing need for capillaroscopy in rheumatology. Arthritis Rheum (Arthritis Care & Res) 61:405–410CrossRef De Angelis R, Grassi W, Cutolo M (2009) A growing need for capillaroscopy in rheumatology. Arthritis Rheum (Arthritis Care & Res) 61:405–410CrossRef
11.
go back to reference Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S, Ciołkiewicz M (2007) Vascular endothelial growth factor (VEGF) in systemic lupus erythematosus: relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalities. Arch Immunol Ther Exp 55:179–185CrossRef Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S, Ciołkiewicz M (2007) Vascular endothelial growth factor (VEGF) in systemic lupus erythematosus: relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalities. Arch Immunol Ther Exp 55:179–185CrossRef
12.
go back to reference Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S (2001) Serum autoantibodies profile and increased levels of circulating intercellular adhesion molecule-1: a reflection of the immunologically mediated systemic vasculopathy in rheumatic diseases? Arch Immunol Ther Exp 49:423–430 Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S (2001) Serum autoantibodies profile and increased levels of circulating intercellular adhesion molecule-1: a reflection of the immunologically mediated systemic vasculopathy in rheumatic diseases? Arch Immunol Ther Exp 49:423–430
13.
go back to reference Lambova SN, Müller-Ladner U (2009) New lines in therapy of Raynaud’s phenomenon. Rheumatol Int 29:355–363CrossRefPubMed Lambova SN, Müller-Ladner U (2009) New lines in therapy of Raynaud’s phenomenon. Rheumatol Int 29:355–363CrossRefPubMed
14.
go back to reference Herrick AL (2011) Contemporary management of Raynaud’s phenomenon and digital ischaemic complications. Curr Opin Rheumatol 23:555–561CrossRefPubMed Herrick AL (2011) Contemporary management of Raynaud’s phenomenon and digital ischaemic complications. Curr Opin Rheumatol 23:555–561CrossRefPubMed
15.
go back to reference Malenfant D, Catton M, Pope JE (2009) The efficacy of complementary and alternative medicine in the treatment of Raynaud’s phenomenon: a literature review and meta-analysis. Rheumatology 48:791–795CrossRefPubMed Malenfant D, Catton M, Pope JE (2009) The efficacy of complementary and alternative medicine in the treatment of Raynaud’s phenomenon: a literature review and meta-analysis. Rheumatology 48:791–795CrossRefPubMed
16.
go back to reference Hirschl M, Katzenschlager R, Francesconi C, Kundi M (2004) Low level laser therapy in primary Raynaud’s phenomenon—results of a placebo controlled, double blind intervention study. J Rheumatol 31:2408–2412PubMed Hirschl M, Katzenschlager R, Francesconi C, Kundi M (2004) Low level laser therapy in primary Raynaud’s phenomenon—results of a placebo controlled, double blind intervention study. J Rheumatol 31:2408–2412PubMed
17.
go back to reference Al-Awami M, Schillinger M, Gschwandter ME, Maca T, Haumer M, Minar E (2001) Low level laser treatment of primary and secondary Raynaud’s phenomenon. VASA 30:281–284CrossRefPubMed Al-Awami M, Schillinger M, Gschwandter ME, Maca T, Haumer M, Minar E (2001) Low level laser treatment of primary and secondary Raynaud’s phenomenon. VASA 30:281–284CrossRefPubMed
18.
go back to reference Gworys K, Gasztych J, Puzder A, Gworys P, Kujawa J (2012) Influence of various laser therapy methods on knee joint pain and function in patients with knee osteoarthritis. Ortop Traumatol Rehabil 14:262–277CrossRef Gworys K, Gasztych J, Puzder A, Gworys P, Kujawa J (2012) Influence of various laser therapy methods on knee joint pain and function in patients with knee osteoarthritis. Ortop Traumatol Rehabil 14:262–277CrossRef
19.
go back to reference Hegedus B, Viharos L, Gervain M, Galfi M (2009) The effect of low-level laser therapy in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial. Photomed Laser Surg 27:577–584CrossRefPubMedCentralPubMed Hegedus B, Viharos L, Gervain M, Galfi M (2009) The effect of low-level laser therapy in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial. Photomed Laser Surg 27:577–584CrossRefPubMedCentralPubMed
20.
go back to reference Konstatinovic LM, Cutavic MR, Milovanovic AN (2010) Low level laser therapy for acute neck pain with radiculopathy: a double-blind placebo-controlled randomized study. Pain Med 11:1169–1178CrossRef Konstatinovic LM, Cutavic MR, Milovanovic AN (2010) Low level laser therapy for acute neck pain with radiculopathy: a double-blind placebo-controlled randomized study. Pain Med 11:1169–1178CrossRef
21.
go back to reference Hashimi JT, Huang YY, Sharma SK (2010) Effect of pulsing in low-level light therapy. Lasers Surg Med 42:450–466CrossRef Hashimi JT, Huang YY, Sharma SK (2010) Effect of pulsing in low-level light therapy. Lasers Surg Med 42:450–466CrossRef
22.
go back to reference LeRoy EC, Medsger TA Jr (1992) Raynaud’s phenomenon-aproposal for classification. Clin Exp Rheumatol 10:485–488PubMed LeRoy EC, Medsger TA Jr (1992) Raynaud’s phenomenon-aproposal for classification. Clin Exp Rheumatol 10:485–488PubMed
23.
go back to reference Matucci-Cerinic M, Allanore Y, Czirjak L, Tyndall A, Muller-Ladner U, Denton C et al (2009) The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research Group (EUSTAR) community: it is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis 68:1377–1380CrossRefPubMed Matucci-Cerinic M, Allanore Y, Czirjak L, Tyndall A, Muller-Ladner U, Denton C et al (2009) The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research Group (EUSTAR) community: it is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis 68:1377–1380CrossRefPubMed
24.
go back to reference Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C et al (2011) Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi consensus study from EULAR scleroderma trials and research group. Ann Rheum Dis 70:476–481CrossRefPubMed Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C et al (2011) Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi consensus study from EULAR scleroderma trials and research group. Ann Rheum Dis 70:476–481CrossRefPubMed
25.
go back to reference Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefPubMed Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefPubMed
26.
go back to reference Mosca M, Neri R, Bombardieri S (1999) Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 17:615–620PubMed Mosca M, Neri R, Bombardieri S (1999) Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 17:615–620PubMed
27.
go back to reference Filaci G, CutoloM BM, Murdaca G, Derchi L, Gianrossi R et al (2001) Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Rheumatology (Oxford) 40:1431–1432CrossRef Filaci G, CutoloM BM, Murdaca G, Derchi L, Gianrossi R et al (2001) Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Rheumatology (Oxford) 40:1431–1432CrossRef
28.
go back to reference Ingegnoli F, Boracchi P, Gualtierotti R, Biganzoli EM, Zeni S, Lubatti C et al (2010) Improving outcome prediction of systemic sclerosis from isolated Raynaud’s phenomenon: role of autoantibodies and nail-fold capillaroscopy. Rheumatology 49:797–805CrossRefPubMed Ingegnoli F, Boracchi P, Gualtierotti R, Biganzoli EM, Zeni S, Lubatti C et al (2010) Improving outcome prediction of systemic sclerosis from isolated Raynaud’s phenomenon: role of autoantibodies and nail-fold capillaroscopy. Rheumatology 49:797–805CrossRefPubMed
29.
go back to reference Herrick AL, Cutolo M (2010) Clinical implications from capillaroscopic analysis in patients with Raynaud’s phenomenon and systemic sclerosis. Arthritis Rheum 62:2595–2604CrossRefPubMed Herrick AL, Cutolo M (2010) Clinical implications from capillaroscopic analysis in patients with Raynaud’s phenomenon and systemic sclerosis. Arthritis Rheum 62:2595–2604CrossRefPubMed
30.
go back to reference Lambova SN, Hermann W, Müller-Ladner U (2012) Comparison of qualitative and quantitative analysis of capillaroscopic findings in patients with rheumatic diseases. Rheumatol Int 32:3729–3735CrossRefPubMed Lambova SN, Hermann W, Müller-Ladner U (2012) Comparison of qualitative and quantitative analysis of capillaroscopic findings in patients with rheumatic diseases. Rheumatol Int 32:3729–3735CrossRefPubMed
31.
go back to reference Meli M, Gitzelmann G, Koppensteiner R, Amann-Vesti BR (2006) Predictive value of nailfold capillaroscopy in patients with Raynaud’s phenomenon. Clin Rheumatol 25:153–158CrossRefPubMed Meli M, Gitzelmann G, Koppensteiner R, Amann-Vesti BR (2006) Predictive value of nailfold capillaroscopy in patients with Raynaud’s phenomenon. Clin Rheumatol 25:153–158CrossRefPubMed
32.
go back to reference Sebastiani M, Manfredi A, Colaci M, D’Amico R, Malagoli V, Giuggioli D, Ferri C (2009) Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum 61:688–694CrossRefPubMed Sebastiani M, Manfredi A, Colaci M, D’Amico R, Malagoli V, Giuggioli D, Ferri C (2009) Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum 61:688–694CrossRefPubMed
33.
go back to reference Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G et al (2008) Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis. Arthritis Rheum 58:3902–3912CrossRefPubMed Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G et al (2008) Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis. Arthritis Rheum 58:3902–3912CrossRefPubMed
34.
go back to reference Giducci S, Bellando Randone S, Bruni C, Carnesecchi G, Maresta A, Iannone F et al (2012) Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clin Rheumatol 31:1723–1725CrossRef Giducci S, Bellando Randone S, Bruni C, Carnesecchi G, Maresta A, Iannone F et al (2012) Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clin Rheumatol 31:1723–1725CrossRef
35.
go back to reference Aschwanden M, Daikeler T, Jaeger KA, Thalhammer C, Gratwohl A, Matucci-Cerinic M et al (2008) Rapid improvement of nailfold capillaroscopy after intense immunosuppression for systemic sclerosis and mixed connective tissue disease. Ann Rheum Dis 67:1057–1059CrossRefPubMed Aschwanden M, Daikeler T, Jaeger KA, Thalhammer C, Gratwohl A, Matucci-Cerinic M et al (2008) Rapid improvement of nailfold capillaroscopy after intense immunosuppression for systemic sclerosis and mixed connective tissue disease. Ann Rheum Dis 67:1057–1059CrossRefPubMed
36.
go back to reference Gladue H, Maranian P, Paulus HE, Khanna D (2013) Evaluation of test characteristics for outcome measures used in Raynaud’s phenomenon clinical trials. Arthritis Care Res (Hoboken) 65:630–636CrossRef Gladue H, Maranian P, Paulus HE, Khanna D (2013) Evaluation of test characteristics for outcome measures used in Raynaud’s phenomenon clinical trials. Arthritis Care Res (Hoboken) 65:630–636CrossRef
37.
38.
go back to reference Kuryliszyn-Moskal A, Ciołkiewicz M, Klimiuk PA, Sierakowski S (2009) Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity. Scand J Rheumatol 38:38–45CrossRefPubMed Kuryliszyn-Moskal A, Ciołkiewicz M, Klimiuk PA, Sierakowski S (2009) Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity. Scand J Rheumatol 38:38–45CrossRefPubMed
39.
go back to reference Michalska-Jakubus M, Kowal-Bielecka O, Chodorowka G, Bielecki M, Krasowska D (2011) Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease. Rheumatology (Oxford) 50:746–755CrossRef Michalska-Jakubus M, Kowal-Bielecka O, Chodorowka G, Bielecki M, Krasowska D (2011) Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease. Rheumatology (Oxford) 50:746–755CrossRef
Metadata
Title
The influence of Multiwave Locked System (MLS) laser therapy on clinical features, microcirculatory abnormalities and selected modulators of angiogenesis in patients with Raynaud’s phenomenon
Authors
Anna Kuryliszyn-Moskal
Jacek Kita
Agnieszka Dakowicz
Sylwia Chwieśko-Minarowska
Diana Moskal
Bożena Kosztyła-Hojna
Ewa Jabłońska
Piotr Adrian Klimiuk
Publication date
01-03-2015
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 3/2015
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-014-2637-8

Other articles of this Issue 3/2015

Clinical Rheumatology 3/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.